Why the study?
Does an individually optimized, reduced bolus dose of nadroparin provide safe and effective anticoagulation in hemodialysis patients with and without bleeding risk?
Does an individually optimized, reduced bolus dose of nadroparin provide safe and effective anticoagulation in hemodialysis patients with and without bleeding risk?
Individually optimized, reduced doses of nadroparin can provide safe and effective anticoagulation during hemodialysis in patients with and without diabetes and bleeding risk.
Answers are grounded in this paper and cite their sources.
May support individualized nadroparin dosing in hemodialysis; leaves open randomized confirmation in bleeding-risk patients.
The risk of bleeding is a well-known complication in patients on hemodialysis (HD). The aim of this prospective study was to determine the lowest single bolus dose of low-molecular-weight heparin nadroparin for safe and effective HD in patients with a bleeding risk. Forty HD patients were divided into 4 subgroups with 10 participants (diabetics with and without a bleeding risk, nondiabetics with and without a bleeding risk). The actual starting bolus dose was decreased by 25% after the initial 4 weeks, further decreased by 25% of the starting dose after 4 weeks, and changed due to extracorporeal circuit clotting in the last 4 weeks. The parameters of coagulation were measured at the beginning, after 2 and 4 h of HD sessions. A significant reduction of nadroparin (first vs. last HD session) was observed in: diabetics with a bleeding risk (49.66 ± 12.33 vs. 28.78 ± 9.60 IU/kg/HD; P<0.001), diabetics without a bleeding risk (50.70 ± 15.23 vs. 33.95 ± 16.97 IU/kg/HD; P<0.001), and nondiabetics with a bleeding risk (61.25 ± 18.68 vs. 32.96 ± 10.06 IU/kg/HD; P<0.001). Altogether, the reduction of the nadroparin dose in these groups was 42.05%; 33.04%, and 46.19%, respectively. Although anti-Xa at hour 4 at the end of the study was <0.4 IU/mL in our diabetic and nondiabetic patients without a risk of bleeding, serious clottings in the extracorporeal circuit and vascular access thromboses were not found. This study demonstrated for the first time that individually optimized doses of nadroparin are sufficient for safe and effective HD in patients with a bleeding risk.
No takes yet. Share an insight, caveat, or question.
Šain et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: